• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Society of Nephrology (ASN) - Kidney Week 2025

November 5 - 9, 2025

  1. aHUS
  2. CSA-AKI
  3. HSCT-TMA
  4. HypoPT
  5. IgAN
  6. LN
  7. Other

html

Baseline characteristics and treatment patterns in chinese patients with atypical hemolytic uremic syndrome: preliminary results from a prospective, observational study

PDF

Ravulizumab in atypical hemolytic uremic syndrome: time-to-treatment analysis from a phase 3 trial

PDF

Real-world effectiveness of ravulizumab among patients with atypical hemolytic uremic syndrome (aHUS) in underrepresented minority subgroups: a physician panel-based chart review study

pdf

Long-term clinical impact of cardiac surgery-associated AKI in patients with stage 3 or 4 CKD: LOTUS study

pdf

Ravulizumab treatment in pediatric patients with HSCT-TMA is associated with lower rates of hypertension, proteinuria reduction, and high survival

pdf

Eneboparatide Induces normalization of urinary calcium in hypoparathyroidism through prolonged PTH1R activation

HTML

Blood pressure control in patients with IgA nephropathy on ravulizumab: prespecified analysis of the phase 2 SANCTUARY trial

PDF

Change in soluble biomarker levels in patients with IgAN: analysis of the phase 2 trial of ravulizumab (SANCTUARY)

HTML

Soluble Biomarkers in IgAN: Analysis of Baseline Data from the Phase 2 Trial of Ravulizumab (SANCTUARY)

pdf

Efficacy and safety of ALXN2050 in IgAN: results of a randomized, double-blind, placebo-controlled phase 2 trial

pdf

Efficacy of ravulizumab on proteinuria response by baseline proteinuria or eGFR: post hoc analysis of the SANCTUARY trial

pdf

Evaluation of hematuria in patients treated with ravulizumab in the phase 2 SANCTUARY trial

pdf

Prespecified analysis of expanded safety outcomes of ravulizumab in IgAN from the SANCTUARY trial

pdf

Proteomic profiling of 24-hour urine in the phase 2 IgAN SANCTUARY trial

PDF

Efficacy and safety of ALXN2050 (vemircopan) in lupus nephritis: results of a phase 2 trial

PDF

Pregnancy outcomes following ravulizumab exposure: a pharmacovigilance analysis

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States (Take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2025 AstraZeneca. All rights reserved.

US-69609; US-91816; US-103094; US-106788

Last Updated 11/25

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Privacy Notice

Legal Notice

Cookie Preferences

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Pharma Logo

Privacy NoticeLegal NoticeCookie Preferences